Riluzole and ALS therapy

Wiener Medizinische Wochenschrift

Volumn 146, Issue 9-10, 1996, Pages 185-187

  Hugon, J ^a  

^a UNIVERSITY OF LIMOGES   (France)

Author keywords

amyotrophic lateral sclerosis; excitotoxicity; motoneuron; riluzole

Indexed keywords

PLACEBO; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MOTONEURON; SHORT SURVEY; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MOTOR NEURONS; NEUROLOGIC EXAMINATION; RILUZOLE; SURVIVAL ANALYSIS; THIAZOLES;

EID: 0029679762     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, Gueremy C, Le Fur G: 2-amino-6-trifluoromethoxy benzothiazole. a possible antagonist of excitatory amino acid neurotransmission - II Biochemical aspects, Neuropharmacology 1985;24:1085.
2. Benazzouz A, Boraud T, Dubedat P, Stutzmann JM, Gross C: Riluzole prevents MPTP-induced parkinsonism in rhesus monkeys: a pilot study. Soc Neurosci Abst 1994;20:670.13.
3. Benoit E, Escande D: Riluzole specifically blocks inactivated sodium channels in myelinated nerve fibers. Pfluger's Arch 1991;419:603.
4. Bensimon G, Lacomblez L, Meininger V, and the ALS/riluzole study group: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
5. +-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 1994;5:2157.
6. Boireau A, Dubedat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A: Riluzole and experimental parkinsonism: antagonism of MPTP induced decrease in central dopamine levels in mice. Neuroreport 1994;5:2657.
7. Bonfoco E, Kraine D, Ankarerona M, Nicotera P, Lipton SA: Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995;92:7162-7166.
8. Brady S: Interfering with the runners. Nature 1995;375:12-13.
9. Cheramy A, Barbeito L, Godeheu G, Glowinski J: Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209.
10. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
11. Cote F, Collard JF, Julien JP: Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993;73:35-46.
12. Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M: Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/Kainate receptors. Lancet 1993;341:265-268.
13. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J: Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5:1012.
14. Doble A, Hubert JP, Blanchard JC: Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-(3H) aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992;140:251.
15. Figlewicz DA, Krizus A, Martinoli MG, Meininger V, Dib M, Rouleau GA, Julien JP: Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Molecular Genetics 1994;3:1757-1761.
16. Glen Smith R, Alexianu ME, Crawford F, Nyormoi O, Stefani E, Appel SH: Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc Natl Acad Sci USA 1994;91:3393-3397.
17. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng Hx, Chen W, Zhai P, Sufit R, Siddique T: Motor neuron degeneration in mice that express a human Cu.Zn Superoxide dismutase mutation. Science 1994;264:1772-1775.
18. Hugon J: Excitotoxic blocking strategies in amyotrophic lateral sclerosis, in Serratrice G, Munsat T (eds): Pathology and Therapy of Amyotroph Lateral Sclerosis. Advances in Neurology 1995;68:245-252.
19. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
20. Malgouris C, Bardot F, Daniel M, Mellis F, Rataud J, Uzan A, Blanchard JC, Laduron PM: Riluzole a nouvel antiglutamate prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989;9:3720.
21. Martin D, Thompson MA, Nadler JV: The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250:473.
22. Rosen DR, Siddique T, et al: Mutations in Cu. Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
23. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch BL, Choyle JT: Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
24. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic Lateral sclerosis. Ann Neurol 1995;38:73-84.
25. Sendtner M, Thoenen H: Oxidative stress and motoneuron disease. Curr Biol 1994;4:1036-1039.
26. Sindou P, Couratier P, Esclaire F, Yardin C, Bousseau A, Hugon J: Prevention of HIV coat protein (gp 120) toxicity in cortical cell cultures by riluzole. J Neurol Sci 1994;126:133.
27. Smith RG, Hamilton S, Hofmann F, et al: Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992;327:1721-1728.